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Abstract--The bioactive lipid, sphingosine 1-phosphate (S1P) is produced by phosphorylation 
of sphingosine and this is catalysed by two sphingosine kinase isoforms (SK1 and SK2).  Here 
we discuss structural functional aspects of SK1 (which is a dimeric  quaternary enzyme) that 
relate to coordinated coupling of membrane association with phosphorylation of Ser225 in the 
so-called R-loop, catalytic activity and protein-protein interactions (e.g. TRAF2, PP2A and 
Gq).  S1P formed by SK1 at the plasma-membrane is released from cells via S1P transporters 
to act on S1P receptors to promote tumorigenesis.  We discuss here an additional novel 
mechanism that can operate between cancer cells and fibroblasts and which involves the 
release of the S1P receptor, S1P2 in exosomes from breast cancer cells that regulates ERK-1/2 
signalling in fibroblasts.  This novel mechanism of signalling might provide an explanation 
for the role of S1P2 in promoting metastasis of cancer cells and which is dependent on the 
micro-environmental niche. 
2Introduction--The bioactive lipid, sphingosine 1-phosphate (S1P) is produced by 
phosphorylation of sphingosine using ATP and this is catalysed by two sphingosine kinase 
isoforms (SK1 and SK2).  These enzymes are encoded by distinct genes and differ in their 
subcellular localisation, biochemical properties and functions.  S1P can either be exported 
from cells to bind to a family of five S1P-specific G protein coupled receptors (S1P1-5) or can 
interact with specific intracellular target proteins, such as human telomerase reverse 
transcriptase (hTERT), to induce cell responses (Pyne et al., 2016).  A role for S1P in cancer 
is suggested from studies demonstrating that high expression of SK1, SK2 and S1P receptors 
in tumours is linked with poor prognosis in patients (Watson et al., 2010; Ohotski et al., 2013; 
Wang et al., 2014a).  There is also substantial evidence for a role for S1P in promoting 
transformation, epithelial mesenchymal transition and invasiveness, cancer cell survival, 
replicative immortality, tumour neovascularisation and aerobic glycolysis; the so-called 
hallmarks of cancer (Pyne and Pyne, 2010; Pyne et al., 2016; Maczis et al., 2016).  Therefore, 
both SK1 and SK2 are potential targets for therapeutic intervention in cancer.  Transformation 
of NIH3T3 cells into fibrosarcoma can be achieved by over-expression of SK1 (Xia et al., 
2000) and this involves its translocation from the cytoplasm to the plasma-membrane, a process 
that allows access to substrate (sphingosine).  In this regard, cancer cells exhibit a non-
oncogenic addiction for SK1 (Vadas et al., 2008).  Indeed, over-expression of a kinase-dead 
G82D SK1 mutant fails to induce transformation, thereby demonstrating dependency on the 
3catalytic activity of SK1 and therefore on S1P (Xia et al., 2000).  A key step in the 
transformation process is the phosphorylation of SK1 by extracellular regulated kinase (ERK) 
on Ser225, which promotes translocation of the enzyme from the cytoplasm to the plasma-
membrane (Pitson et al., 2003; Pitson et al., 2005).  Indeed, constitutive localisation of a 
phosphorylation deficient mutant of SK1 to the plasma-membrane promotes so called 
oncogenic signalling (Pitson et al., 2005).  Moreover, recent studies have demonstrated that 
SK1 activation and localization to the plasma membrane and subsequent activation of S1P2 
by released S1P (inside-out signalling) increases transferrin receptor 1 (TFR1) expression 
(Pham et al., 2014).  Moreover, inhibition of TFR1 with a neutralising antibody prevents 
SK1-induced proliferation, survival and neoplastic transformation of NIH3T3 fibroblasts 
(Pham et al., 2014).  In addition, recent evidence demonstrates a role for SK1 in endosomal 
processing (Shen et al., 2014).  In this regard, depletion of cholesterol/sphingomyelin in the 
plasma membrane induces the formation of clusters of narrow endocytic tubular 
invaginations that are positive for N-BAR proteins and SK1 in various mammalian cell lines 
(Shen et al., 2014).  The association with early endosomes occurs via a hydrophobic patch 
located in the lipid binding loop-1 (LBL-1) of SK1 and this occurs in a curvature-sensitive 
manner (vide infra).  Moreover, knockdown of SK1 produces endocytic recycling defects 
(Shen et al., 2014).  The regulation of endocytic recycling by SK1 might, therefore, impact 
significantly on disease forming mechanisms in cancer.  Taken together, these findings 
suggest that the redistribution of SK1 from the cytoplasm to the plasma-membrane/endosomes 
requires more thorough understanding from a structural/functional perspective. 
In this review, we discuss structure-function aspects of SK1 that relate to its regulation and 
plasma-membrane association.  SK1 adopts a dimeric quaternary structure and this 
organisation, as we detail below, may allow for coordinated coupling of membrane association 
4with phosphorylation of Ser225 in the so-called R-loop, catalytic activity and protein-protein 
interactions (e.g. TRAF2, PP2A and Gq).  Plasticity in the ATP binding domain appears to be 
important for catalytic operation and is likely modulated by a helix-capping mechanism 
involving the regulatory C-terminal protein-binding sequence, also discussed below (Adams 
et al., 2016).  
Current established models for the action of S1P involve its release and binding to S1P 
receptors on recipient cells (Takabe and Spiegel, 2014).  This underlies inter-cellular 
communication between, for instance, cancer cells and fibroblasts in the micro-environmental 
niche that can promote metastatic spread.  Multiple S1P receptors can be expressed in a 
single cell type, and it is currently unclear how S1P signalling through these receptors is 
differentiated to induce specific S1P receptor-mediated cellular response programmes.  One 
possibility is that S1P partitions to the plasma-membrane and is carried by chaperones in a 
controlled process that allows its delivery to specific receptors (Galvani et al., 2015).  
However, we discuss here an additional novel mechanism that can operate between cancer 
cells and fibroblasts and which involves release of the S1P receptor, S1P2, in exosomes from 
breast cancer cells (unpublished).  The released S1P2 is then proteolysed by fibroblasts to 
produce a constitutively active form (S1P independent) that regulates the ERK-1/2 pathway 
in fibroblasts and promotes their proliferation.  This novel mechanism of signalling might 
provide an explanation for the role of S1P2 in promoting metastasis of cancer cells and which 
involves expansion of the fibroblast population. 
Structural features of sphingosine kinase 1--SK1 has a two-domain structure with an N-
terminal domain (NTD) hosting the binding site for ATP and a C-terminal domain (CTD) 
containing the binding site for sphingosine (Figure 1) (Wang et al., 2013). The inter-domain 
5junctional cleft hosts the catalytic centre. The NTD is composed of an GHG sandwich 
containing six H, 1H,H: and HI6 and six G,  1G,G$6
  The CTD domain is 
organised into a two-layer H,'  containing 11 H, 1H$,H$6
 Three extended 
loops between strands HE,HJ H),H and H,H7 contribute to the sphingosine (Sph) 
binding site.  These are called lipid binding loops 1-3 (LBL-1 to LBL-3). LBL-1 folds with 
two reverse-paired helices 1GI,GE6 with the inter-helix connection positioned into the 
catalytic cleft.  The shorter LBL-2 interfaces with the NTD at the catalytic cleft and lacks 
secondary structure.  LBL-3 contains an additional helix 1GJ6 that runs antiparallel along GE 
and does not make direct contact with the NTD. The binding site for sphingosine lies between 
GI,GJ and interfaces with the H,'  of CTD. The reverse face of this H,'  
contains a regulatory loop (R-loop) which is present between strands HJH) and contains 
the ERK phosphorylation site at Ser225 (Pitson et al., 2003). 
The nucleotide binding site in SK1 involves a number of key structural motifs (Figure 1, 
inset) (Wang et al., 2013).  The adenine makes contact with residues 22-NPR-24 (motif-1) 
and 54-TERR-57 (motif-2).  A third motif (79-SGDGLMHE-86, motif-3) makes contact with 
the -phosphate of the nucleotide and is often referred to as the P-loop.  The -phosphate is 
engaged by motif-4 (111-GSGNAL-116), referred to as the T-loop.  A catalytic Mg2+ ion, 
that coordinates to the nucleotide phosphates, is bound to a DGE sequence (motif-5) through 
the carboxylate of Glu343 and backbone carbonyl of Asp341.  In SK1 crystal structures with 
bound ADP, the -phosphate is seen to interact with Arg185 and Arg191 present in LBL-1.  
However, Arg191 might potentially be involved in binding the ATP -phosphate and the S1P 
product during actual catalytic operation.
6Sphingosine is accommodated in the so-called J-channel, where there is surface contact 
with hydrophobic residues in LBL-1-3 and across the face of the CTD H,'  core.  The 
Sph-1-OH is positioned in loose contact with P-loop Asp81 (Figure 1, inset), which serves as 
the base to deprotonate sphingosine and allow transfer of the -phosphate from ATP by 
nucleophilic attack (Wang et al., 2013).  The Sph-3-OH engages Asp178 on LBL-1 to anchor 
the substrate head group in the mouth of the J-channel.
Regulation of plasma-membrane association of SK1--Transformation of normal cells into 
cancer cells by SK1 involves the enzymes translocation from the cytoplasm to the plasma-
membrane, where it can access its substrate, sphingosine.  There are multiple factors that 
govern the translocation of SK1 to the plasma-membrane and its subsequent residence there.  
One regulatory mechanism involves the phosphorylation of Ser225 in SK1 by ERK, which 
promotes both membrane targeting and enhanced activity of the enzyme (Pitson et al., 2003; 
Pitson et al., 2005)].  Interactions with acidic phospholipids, notably with phosphatidylserine 
(PS) (Olivera et al., 1996; Stahelin et al., 2005), also play a key role in the activation and 
membrane localisation of SK1. It has been proposed that the enzyme hosts a specific 
recognition site for the lipid head group of PS that might potentially be exposed upon 
phosphorylation of Ser225 by ERK.  In particular, Thr54 and Asn89 have been identified as 
residues in SK1 that are important for interaction of the enzyme with PS at the plasma-
membrane (Stahelin et al., 2005; Hengst et al., 2009), although it is not known whether the 
residues themselves interact directly with PS.  
The structural change in SK1 elicited by phosphorylation of Ser225 in the R-loop has yet to 
be defined.  Curiously, in the available SK1 crystal structures (Wang et al., 2013; Gustin et 
al., 2013; Wang et al., 2014b), Ser225 is seen to occupy a prominently solvent-exposed 
7position (Figure 2).  A regulatory mechanism in which phosphorylation simply lifts the R-
loop from the surface of the protein appears inconsistent with this pre-exposed position for 
Ser225.  Clues as to the possible structural impact of the phosphorylation are, however, 
suggested by the observed interaction of the R-loop with the NTD of SK1.  Thus, in the 
available crystal structures, when the tip of the R-loop is ordered it is found packed against a 
sequence (93-ERPDW-97) located at the G,A( junction in the NTD (Figure 2).  R-loop 
movement induced by phosphorylation may therefore conceivably perturb this CTD-NTD 
interface.  Asn89, one of the residues known to be important for targeting of SK1 to PS-
enriched sites (Stahelin et al., 2005), is proximally located on >,GA and also makes a key 
cross-domain contact in the form a doubly hydrogen bonded interaction across the inter-
domain cleft to the backbone of Phe164 on CTD HI
  Taken together, these considerations 
suggest that inter-domain movement and/or perturbation of residues distributed across GA( 
may be important to the interaction with PS and therefore to membrane residence of SK1.  
One possible mechanism by which phosphorylation might elicit such a perturbation could 
involve displacement of R-loop aspartate, Asp235, from a basic pocket on the SK1 CTD 
lined by His156/Arg162/His355 (Adams et al., 2016).  Crystal structures suggest that docking 
of Asp235 into this site (Figure 2) likely plays an important role in stabilising the basal state 
R-loop conformation and cross-domain interaction with the G,A( junction.  The position of 
Ser225 is such that in its phosphorylated state it might potentially target the Asp235 binding 
locus, which would then displace the R-loop tip from its NTD engagement. We have 
proposed (Adams et al., 2016) that conformational relaxation in the SK1ERPD sequence at 
the G,A( junction modulates a region of positive electrostatic potential surface proximal to 
the SK1 dimerisation interface (cf. Figure 3) and to Thr54 (a residue also known to be 
important for the interaction of SK1 with PS). 
8Whilst residence of the enzyme at the plasma-membrane may be subject, at least in part, to 
interaction with acidic phospholipids, the translocation process itself may be facilitated by 
additional factors. In particular, association with calcium and integrin-binding protein 1 
(CIB1) has been shown to play a role in the enzymes translocation (Jarman et al., 2010).  
Intriguingly, surface-exposed hydrophobic residues (Phe197/Leu198) on >,GE of LBL-1, 
that have been implicated in the interaction of SK1 with CIB1, may also be involved in the 
direct interaction of SK1 with the membrane itself following translocation, potentially by 
immersion within the membrane.  Thus, mutation of these residues or (separately) the 
adjacent Leu194, so as to compromise an exposed hydrophobic patch on >,GE (Figure 3), 
blocks binding of SK1 both to acidic liposomes in vitro and curvature-sensitive membrane 
association of SK1 in living cells (Sutherland et al., 2006; Shen et al., 2014).  This suggests 
that membrane residence may involve a combination of polar interactions between SK1 and 
acidic membrane phospholipids augmented by insertion of LBL-1 into the membrane. 
Such a model raises questions about the overall topology of the protein and its approach to 
the membrane surface.  We have reported that SK1 adopts a functionally significant dimeric 
quaternary structure (Lim et al., 2011), which likely corresponds to the dimeric assembly 
seen in all five of the currently available SK1 crystal structures.  Dimerisation in the crystal 
lattices involves partial annealing of the exposed H7 strands (Figure 1) from two adjacent 
protein subunits to generate a C2-symmetric NTD-NTD interface that also involves 
interactions with residues in the helices that flank H7 on either face.  A common pattern of 
head-to-head dimerization is widely seen across structurally related prokaryotic lipid kinase 
enzymes belonging to the diacylglycerol kinase DAGK_cat family (Pfam 00781) (Adams et 
al., 2016).  In the case of SK1, this mode of dimerisation generates a pronounced groove at 
the dimer interface which is aligned parallel with the >,GE axes from the two LBL-1 loops 
9of the dimer, these being offset on either side of the central groove (Figure 3).  The groove 
exhibits significant net positive charge density and a structure that might potentially be 
sensitive to modulation by phosphorylation of the R-loop according to the relay mechanism 
postulated in Figure 2.  Significantly, the exposed >,GE hydrophobic surfaces map to the 
same face of the SK1 dimer so that docking of the positively charged groove to the 
membrane surface might allow simultaneous insertion of the LBL-1 loops into the 
membrane.  An intriguing consequence of the dimeric structure with the central groove, 
therefore, is that topologically the protein might be optimally suited for binding in a dimeric 
state to a membrane surface exhibiting positive curvature, as illustrated in Figure 3 panel A 
(ii).  Such a model could then account for the findings of Shen et al., (2014), who have 
recently reported that membrane recruitment of SK1 in living cells involves a direct, 
curvature-sensitive interaction with the lipid bilayer and a pronounced preference for regions 
of high positive curvature, notably at narrow tubular membrane invaginations thought to 
correspond to early endocytic structures.  We have therefore proposed that SK1 recruitment 
to such structures may be facilitated by alignment of the dimer cleft along the curvature axis 
(Adams et al., 2016).  An important corollary of the proposed membrane engagement mode 
(Figure 3) is that it also provides a plausible rationale for Sph substrate extraction from the 
membrane by a gating mechanism in which helices-7/8 of LBL-1 open to expose the 
hydrophobic surface of the J-channel and then reclose to encapsulate the substrate, thus 
isolating the Sph head group within the enzymes interior for selective phosphoryl transfer 
from ATP.
C-terminal regulation of SK1 activity and translocation to the plasma-membrane--The C-
terminal tail of SK1, which is known to support the binding of partner proteins (vide infra), is 
likely to play an important role in regulating SK1 with potential ramifications for cancer 
disease progression.  Indeed, truncation after residue 363 in the C-terminal tail renders SK1 
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constitutively active and promotes localization to PS-containing lipid raft micro-domains 
(without requirement for phosphorylation of R-loop Ser225) (Hengst et al., 2010).  
Remarkably, the addition of just four residues (364-367) is sufficient to restore the lower 
basal activity of full-length SK1 but in a manner that does not depend on residue identity, 
suggesting a role for the peptide backbone of this region in modulating catalytic activity.  All 
of the currently available SK1 crystal structures are truncated, terminating at Gly364, so that 
the structure and folding of the enzymes C-terminal 20 residues is currently unknown.  
Nevertheless, inspection of the crystal structures does provide clues as to the possible 
mechanism of action of this important sequence region in regulating SK1.  
Gly364 is located immediately adjacent to the exposed C-terminus of the short >,G: at 
the opposite end to the so-called T-loop (Figure 3A), which is involved in ATP binding and 
catalytic activity.  Residues 364-367 are therefore predicted to be suitably positioned for 
capping of >,G: by means of backbone hydrogen donor interactions (Figure 1 inset, black 
arrows).  Any leverage exerted on >,G: by modulation of this proposed helix capping 
arrangement might then be relayed into the catalytic centre to regulate activity.  Comparison 
of SK1 crystal structures with and without bound nucleotide reveals significant changes in 
the conformation of T-loop residues.  Thus, plasticity in the T-loop may be important for 
enzyme function, potentially allowing the T-loop to track the nucleotide H,0"0 with 
backbone hydrogen donor interactions on separation from the N,0"0 of ATP during 
catalytic turnover (Adams et al., 2016).  Leverage on the T-loop associated with modulated 
C-terminal capping of >,G: therefore provides a highly plausible mechanism for 
regulating catalytic activity, with C-terminal capping of >,G: providing a braking 
mechanism.  Removal of the postulated helix cap could then satisfactorily account for the 
observed constitutive activation associated with C-terminal truncation at residue 363.  
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The mechanism by which C-terminal truncation promotes localization to PS-enriched 
membrane structures has yet to be elucidated.  One possibility is that, in the basal state, the C-
terminal sequence folds in an auto-inhibitory manner to hinder presentation of the positively 
charged putative membrane engagement surface of SK1, for example by targeting of the C-
terminal 379-PPEE-382 sequence to critical basic residues required for PS engagement.  In 
this way movement of the C-terminal tail might orchestrate membrane association 
coordinated precisely with increased catalytic activity exerted by changes in capping of helix-
G: and it follows that sequestration of the C-terminal tail by binding proteins could thereby 
regulate both SK1 translocation to the plasma-membrane and catalytic activity.  
Alternatively, the C-terminus might obstruct dimerization, if the PS engagement is dependent 
on the dimeric assembly.  The full extent to which proteins from the SK1 interactome exploit 
the C-terminal tail remains to be determined, but established examples include TRAF2 
(tumour necrosis factor receptor-associated factor 2) (Xia et al., 2002) and PP2A (Barr et al., 
2008), the protein phosphatase responsible for reversing phosphorylation of Ser225.  These 
proteins have been shown, respectively, to bind to the 79-PPEE-382 sequence and to residues 
in the region 368384.  Another example of a possible SK1 tail-binding protein is Gq.  Both 
wild type and constitutively activated forms of Gq (e.g. GqR183C, GqQ209L-EE) have been 
shown (ter Braak et al., 2009) to promote translocation of SK1 to the plasma-membrane 
independently of Ser225 phosphorylation and therefore, we suggest, perhaps by a mechanism 
that involves sequestration of the SK1 C-terminal tail.  Whilst the Gq-binding determinants on 
SK1 remain to be confirmed, the physiological significance of the SK1-Gq interaction is 
evident from studies showing that SK1 is involved in promoting neurotransmission in 
Caenorhabditis elgans (Chan et al., 2012).  Thus, it has recently been demonstrated that SK1 
localisation in presynaptic neuron periactive zones, which contain endocytic proteins for 
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synaptic vesicle recycling, is increased by muscarinic receptor stimulation of Gq/RhoGEF in 
C. elgans (Chan et al., 2012).  Worms expressing an SK1 V268Q mutation, which 
corresponds to a mutation of LBL-1 L194 in mammalian SK1, exhibit a neurotransmission 
defect that is rescued by the expression of WT SK1.  This occurs because the mutant SK1 
fails to translocate to the periactive zone membrane due to the compromised LBL-1 (Shen et 
al., 2014). 
Membrane targeting clearly plays a key role in the functioning of SK1 in cancer.  The 
existence of both phosphorylation-dependent and -independent mechanisms for driving 
localization of SK1 to membranes raises a question as to whether there is any mechanistic 
intersection between the differing modes of localisation at the level of protein structure.  This 
might occur, for example, if the outcome of Ser225 phosphorylation in the SK1 R-loop is to 
destabilise auto-inhibitory C-terminal folding so as to directly expose the enzymes PS-
binding determinants or allow their formation through dimer assembly.  In this way, a unified 
mechanism of action for membrane localization might operate, driven either by 
phosphorylation of Ser225 to release the SK1 tail or by sequestration of the tail through direct 
protein-protein interactions.  If the interaction with PS is dependent on the dimeric assembly 
of SK1, then potentially the SK1 tail (in its basal state) might obstruct dimer assembly. 
The proposed model for membrane engagement of dimeric SK1 (Figure 3) positions the two 
Gly364 tail connection sites on either side of the protein assembly.  As such, the tail sequence 
is predicted to be able to run clear of the membrane surface and to be able to accommodate 
protein binding with the enzyme operationally engaged at the membrane surface.  This is 
required for localization and activation driven by protein binding to the SK1 tail rather than 
by phosphorylation.   
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S1P3 receptor-dependent translocation of SK1--We have demonstrated a key role of 
S1P3/SK1 in regulating the formation of a migratory phenotype in MCF-7 cells (Long et al., 
2010).  S1P binding to S1P3 stimulates activation of the ERK-1/2 pathway, and 
phosphorylated ERK-1/2 accumulates in membrane ruffles/lamellipodia and the nucleus to 
promote MCF-7 cell migration. We also demonstrated that S1P promotes the translocation of 
SK1 from the cytoplasm to the plasma-membrane and that this was blocked by an S1P3 
antagonist (Long et al., 2010).  Since S1P3 is coupled to Gq, it is possible that this G-protein 
is involved in regulating the translocation of SK1 to the plasma-membrane of breast cancer 
cells.  These findings are intriguing as they suggest that S1P binding to S1P3 on the cell 
surface is transduced into an intracellular S1P signal, which, we propose, regulates the 
phosphorylation and activation of PAK65, which is required for actin/phosphorylated ERK-
1/2 redistribution into lamellipodia and cell migration (Long et al., 2010).  We have also 
reported that the siRNA knockdown of SK1 reduces S1P3 mRNA transcript expression in 
MCF-7 cells and that this ablates S1P-stimulated activation of ERK-1/2 in response to S1P 
(Long et al., 2010).   siRNA knockdown of SK1 also ablated the S1P-stimulated formation of 
actin containing membrane ruffles/lamellipodia and restored the formation of focal actin 
adhesion contacts and inhibited migration.  Therefore, SK1 appears to act as a sensor that 
regulates the amplitude of S1P3 receptor signalling. The S1PR3 gene contains predicted ER, 
Sp1, and c-Jun binding sites in its promoter.  Sp1 and c-Jun are regulated by ERK-1/2, and 
therefore this protein kinase might be involved in a positive-feedback loop that regulates 
S1P3 expression and signalling.
SK1 inhibitors--There are two major mechanisms of action of SK1 inhibitors.  First, SK1 
inhibitors (both catalytic and allosteric) can rapidly and reversibly inhibit catalytic activity 
14
(Baek et al., 2013).  Second, SK1 inhibitors induce a longer term (e.g. 24 h) ubiquitin-
proteasomal degradation of SK1, thereby substantially reducing expression of the enzyme in 
cancer cells (Loveridge et al. 2010; Tonelli et al., 2010; Byun et al., 2013). Some SK1 
inhibitors can be considered direct inducers of the proteasomal degradation of SK1. An 
examples is PF-543, which binds to SK1 to induce a conformation that promotes its 
proteasomal degradation (Byun et al., 2013).  Indeed, there is a strong correlation of 
concentration of inhibitor required to induce proteasomal degradation with the Ki for 
inhibition of catalysis.  In contrast, a weak inhibitor of SK1/SK2, such as Ski (SKI-II, 4-[[4-
(4-chlorophenyl)-2-thiazolyl]amino]phenol), can induce activation of the proteasome to 
increase degradation of SK1 (Loveridge et al., 2010).   This is an example of an indirect 
inducer and occurs via an additional inhibition of dihydroceramide desaturase (Des1) 
(McNaughton et al., 2016), an enzyme within the de novo ceramide synthesis pathway, and 
which we propose restrains proteasomal activity. 
Exosomal S1P receptor signalling in cancer-fibroblast microenvironment interactions--There 
is increasing evidence for a role for S1P in regulation of the cancer-fibroblast 
microenvironment niche.  In this regard, Albinet et al., (2014) reported that SK1 produces 
S1P, which is released from melanoma cells and which, in turn, promotes the differentiation 
of fibroblasts into myofibroblasts. SK1 in myofibroblasts then produces S1P, which promotes 
the S1P/S1P3-dependent metastatic spread of melanoma cells, thereby giving rise to 
bidirectional communication between tumour associated fibroblasts and melanoma cancer 
cells.   In addition, Ponnusamy et al., (2012) have reported that host SK1 produces S1P, 
which promotes lung colonization and metastasis via an S1P2-dependent mechanism. Thus, 
reduced systemic S1P inhibits prostate cancer growth in transgenic adenocarcinoma of the 
mouse prostate (TRAMP+/+)Sk1RR mice or lung metastasis in Sphk1RR mice. The loss of SK1 
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promotes the expression of breast carcinoma metastasis suppressor 1 (Brms1) whereas S1P 
binding to S1P2 reduces Brms1 expression in these cancer cells (Ponnusamy et al., 2012).  
Taken together these studies indicate that host S1P (possibly involving stromal interaction) is 
capable of driving cancer metastasis.  However, we describe here an additional, novel 
mechanism by which S1P receptors may regulate stromal-cancer interaction independently of 
S1P.  In this regard, we have recently found that S1P2 (Mr = 42kDa) is shed from MDA-MB-
231 breast cancer cells in exosomes present in conditioned medium (unpublished).  We have 
also shown that S1P2 and CD63 (a marker for exosomes) are co-localised in multi-vesicular 
bodies (MVBs) in breast cancer cells (unpublished).  Exosomal S1P2 is then proteolysed at 
the N-terminus when combined with fibroblasts to produce a smaller constitutively active 
form (Mr =38 kDa), which is taken up by the fibroblast.  The short S1P2 form stimulates the 
ERK-1/2 pathway in fibroblasts and promotes proliferation of these cells.  We have also 
shown that the activation of ERK-1/2 in fibroblasts in response to exosome or conditioned 
medium containing S1P2 is reduced by siRNA knockdown of S1P2 expression in breast 
cancer cells (unpublished).  A schematic summarising this model for the role of S1P2 in 
cancer-fibroblast microenvironment is summarised in Figure 4.
Topographical arrangement of a GPCR in exosomes and uptake into the plasma-membrane of 
recipient cells would place the C-terminal tail of the GPCR on the cytoplasmic side of the 
recipient cell.  This might enable the short form of S1P2 to initiate signalling into the 
intracellular compartment of the recipient cell.  Others have shown that extracellular vesicles 
derived from immortalized human mammary luminal epithelial HB4a and C5.2 cells contain 
S1P3 and S1P4, although the functional significance was not evaluated (Amorim et al., 2014).  
Constitutive activation of S1P2 could occur as a consequence of proteolysis at the N-
terminus, which might normally exert an inhibitory constraint on S1P2 signalling.  Indeed, N-
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terminal proteolysis of GPCRs has been shown to modulate signalling.  For instance, the 
thyroid-stimulating hormone (TSH) receptor is cleaved by a metalloproteinase at the N-
terminus to produce a form of the receptor that is constitutively active by removal of an 
inhibitory N-terminal domain (Couet et al., 1996; Zhang et al., 2000).  
There are several examples of communication between cancer cells and recipient cells 
involving exosomes.  For example, exosomes derived from nasopharyngeal carcinoma 
contain latent membrane protein 1 (LMP1), which can induce ERK and AKT activation in 
recipient cells (Meckes et al., 210). In addition, exosomes derived from mesenchymal stem 
cells (MSC) promote MCF-7 migration via a Wnt-dependent mechanism of breast cancer 
cells (Lin et al., 2013). Lin et al., (2016) have also reported that bone marrow-derived 
mesenchymal stromal cells release exosomes to promote tumour growth.
The functional consequence of the transfer of S1P2 from breast cancer cells to fibroblasts is to 
induce expansion (e.g. increased DNA synthesis and proliferation) of the fibroblast 
population, which is required to initiate and sustain breast cancer metastatic spread.  Future 
studies will require characterisation of the signalling properties of the short S1P2 receptor in 
order to determine its role (if any) in metastatic spread.  This can be explored by over-
expression of the short S1P2 in fibroblasts in vivo in order to establish the effect on metastatic 
spread in breast cancer xenograft mouse models.  
Conclusion--Our studies have provided a mechanistic model for how SK1 can translocate and 
localise with the plasma-membrane to access substrate for production of S1P.  This process is 
critical for cancer progression, dependent on S1P, which acts intracellularly and/or by 
binding to S1P receptors.  In addition, we have provided novel evidence for a role of 
17
constitutively active S1P2 in cancer-fibroblast interactions that might reveal S1P-independent 
actions of this receptor.  Therefore, targeted therapeutics aimed at inhibiting SK1 activity 
and/or promoting its proteasomal degradation and/or inhibiting its translocation to the 
plasma-membrane may offer novel approaches to preventing cancer cell survival.  
Alternatively, inverse agonists of S1P2 might exhibit additional therapeutic utility in terms of 
blocking cancer-fibroblast interactions to prevent metastatic spread.
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Figure Legends
Figure 1.  (Left)  SK1 tertiary structure illustrated with co-crystal structure 3VZB (chain A) 
with sphingosine (Sph; blue surface) occupying the lipid-binding J-channel of the C-terminal 
25
domain (CTD); Mg-ADP (green sphere/pink surface) is superimposed from a separate SK1 
co-crystal structure (3VZD chain C) (Wang et al., 2013).  The regulatory R-loop 
encompassing the ERK1/2 phosphorylation site (Ser225, circled) is fully ordered here, but 
exhibits partial disorder in other chains and crystal structures (especially in the N-terminal 
half including the phosphoacceptor site).  None of the constructs from which the currently 
available SK1 crystal structures have been obtained encompass the C-terminal 20-residue 
sequence (cf. Figure 3), a sequence that facilitates protein binding and that also mediates 
additional regulatory control (Xia et al., 2002; Barr et al., 2008) (Inset, right). Viewed as 
left, but highlighting detail of the catalytic centre of SK1.  Five motifs (motif-1 to motif-5) 
contribute to binding of the nucleotide.  The P-loop (motif-3, blue dotted ribbon) and T-
loop (motif-4, red dotted ribbon) engage the G, and H,0"0 of the nucleotide.  P-loop 
residue Asp81 caps the T-loop and also serves as the base for deprotonation of the Sph-1-OH 
to facilitate transfer of the N,0"0 from ATP during catalytic turnover.  Comparison of 
SK1 crystal structures with and without bound nucleotide show significant changes in the 
conformation of T-loop residues and suggests that plasticity may be important for catalytic 
function, in particular to allow backbone hydrogen donor interactions to track the nucleotide 
H,0"0 on separation from the N,0"0 of ATP.  In the ADP bound structure, the H,
phosphate is engaged by two arginines, R185 and R191 (marked), from lipid binding loop-1 
(LBL-1).  However, Arg191 is also suitably positioned to interact with the N,0"0 of 
ATP and to stabilise the S1P product resulting from catalytic turnover.  Much of the binding 
affinity for Sph derives from hydrophobic surface and van der Waals contact in the J-channel, 
but the lipid is also held by a highly organised network of polar interactions engaging the 
head unit, prominent among which is the hydrogen bonded interaction of the Sph-3-OH with 
the LBL-1 residue, Asp178 (marked).
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Figure 2.  Hypothetical relay mechanism for regulatory control mediated by phosphorylation 
of Ser225 (Adams et al., 2016).  SK1 crystal structures suggest that in the enzyme basal state 
the tip of the R-loop (green ribbon) interfaces with residues (93-ERPDW-97) located at the G,
3/4 junction (orange ribbon) in the N-terminal domain (NTD).  Maintenance of this interface 
is likely dependent on insertion of R-loop aspartate, D235 (marked), into a basic pocket lined 
by His156/Arg162/His355 (not marked).  Displacement of D235 from this site by phospho-
Ser225 (solid black arrow) would disengage the R-loop tip from the 93-ERPDW-97 sequence 
(blue arrows).  This may perturb NTD residues such as glutamate E93 so as to modulate an 
adjacent region of positive electrostatic surface potential (blue ellipse) that might be involved 
in targeting of SK1 to phosphatidylserine (PS)-enriched membrane environments (cf. Figure 
3).  Two residues for which mutation disrupts PS engagement are Thr54 and Asn89 (marked).
Figure 3.  Membrane engagement hypothesis for dimeric SK1 (Adams et al., 2016).  (A) 
Dimeric assembly of SK1 according to the crystallographically observed mode places the two 
LBL-1 loops (cyan ribbon) on the same face of the rod-like dimer structure and on the 
opposite side of the protein to the regulatory R-loop (green ribbon). The dimeric SK1 
structure, viewed orthogonally in panel A(ii), may be topologically suited for binding to 
membranes that are enriched in acidic phospholipids (phosphatidylserine, PS) and that exhibit 
strong positive curvature.  Interaction of membrane PS with a positively charged dimer 
groove would require insertion of the hydrophobic LBL-1 islands into the membrane, 
consistent with the known requirement of F197 and L198 (marked) for membrane binding 
(Shen et al., 2014).  Opening and closure of the flap-like LBL-1 structures (black arrows) 
may allow extraction of sphingosine (Sph) substrate from the membrane for gated entry into 
the enzymes J-channel.  The C-terminal tail sequence (dotted black line), which facilitates 
protein binding and plays a regulatory role (Xia et al., 2002; Barr et al., 2008; Hengst et al. 
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2010), is missing from available SK1 crystal structures but would be connected at Gly364 
(black spheres) on either side of the dimer structure.  The connection site is proximal to the 
C-terminal end of >,G: (orange ribbon, marked in panel A) and may allow for capping-
modulated regulatory control of catalytic turnover by the tail sequence due to leverage on the 
T-loop (also marked in panel A). In the absence of bound protein or phosphorylation on R-
loop Ser225, the tail sequence may potentially fold to obstruct dimerization and/or membrane 
engagement.  (B) Qualitative electrostatic potential surface mapping reveals a groove with 
significant net positive charge (dashed box) that aligns parallel with the axes of two GE 
helices from the dimer LBL-1 loops.  Prominent hydrophobic islands (cyan circles) are 
generated by exposed hydrophobic residues from helices GE (including F197 and L198). We 
postulate that it is the combination of these features with their relative topology in the dimer 
that may confer the enzymes particular membrane localisation determinants.
Figure 4 Schematic model for the release of S1P2 in exosomes from cancer cells and possible 
interaction with fibroblasts.  S1P2 is endocytosed and processed into MVBs in MDA-MB-231 
cells whereupon it is released in exosomes.  We propose that exosomal S1P2 is taken up and 
processed by fibroblasts to a shorter constitutively active form, lacking the N terminus (red), 
where it can activate the ERK pathway to promote proliferation and, in turn, release factors 
that promote metastatic spread.




